Axogen, Inc. Reports Third Quarter 2026 Financial Results
Axogen reported Q3 2026 revenue of $75.8 million, up 26.2% year-over-year, with net income of $2.3 million ($0.04 per share) and adjusted EPS of $0.21. Adjusted EBITDA rose to $13.4 million from $9.2 million, gross margin was 74.8%, and cash plus investments reached $350.1 million after an upsized $225 million net offering, of which $200 million funded the BioCircuit acquisition completed October 1. Commercial payer coverage for Avance now spans roughly 96% of U.S. covered lives following positive decisions from Elevance and Aetna, and the company will begin prostate market development in 2027.
Key figures
- Eps
- 0.04
- Revenue
- 75800000
- Guidance
- FY26 revenue of at least $290 million (at least 29% growth), including at least $7M from BioCircuit; organic revenue at least $283M (+26%); gross margin at least 73%; positive full-year free cash flow
- Revenue Yoy
- 26.2%
- Adjusted eps
- 0.21
- Gross margin
- 74.8%
- Nine month fcf
- 18942000
- Adjusted ebitda
- 13400000
- Adjusted net income
- 13100000
- Cash and investments
- 350100000
- Net offering proceeds
- 225000000
- Payer coverage covered lives
- 96%
- Biocircuit acquisition funding
- 200000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.